AYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome.
After the bullish news, AYTU stock hit the all time low level.
52 Week Range 0.76 - 7.20
LADENBURG THALM has a price target of $14.50 for the stock.
I think a reversal is...
Moleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases.
the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward.
This should be an interesting year for MBRX, which...
Acurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome.
In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI.
The Company...
